微创医疗预计2024年收入同比增长近10%
3月9日，微创医疗（00853）发布公告，预计截至2024年12月31日的年度业绩将实现近10%的收入增长，尽管面临快速变化的外部环境和行业政策影响。根据初步评估，预计净亏损不超过2.75亿美元，较上年同期的亏损收窄超过58%。这一预期亏损的显著收窄主要归因于公司在报告期内实施的资源聚焦和成本优化措施，使得经营费用占收入比率同比下降约28个百分点。
此外，微创医疗在报告期内通过全球化平台的协同效应，推动出海业务收入同比增长约80%。公司还完成了数家非核心业务的出售，带来正向收益。
同时，报告期内共计6款产品进入国家创新医疗器械审批程序，累计达到36款，连续十年在同行业中排名第一。未来，公司将继续优化和处置亏损及非核心业务，努力实现扭亏为盈的目标，并提升财务健康度。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10